What You Should Know: - Sanofi has agreed to acquire Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), for $25.00 per share in cash, representing an equity value of approximately $2.9B. - The acquisition is a strategic fit for Sanofi at the intersection of the company’s growth in immune-mediated diseases and disease-modifying therapies in areas of high unmet
Read More
biopharmaceutical
Report: Pharma R&D ROI Falls to Lowest Level in 13 Years
What You Should Know: - Deloitte Centre for Health Solutions releases its thirteenth annual report, ‘Seize the Digital Momentum: Measuring the return from pharmaceutical innovation 2022’ that explores the performance of the biopharmaceutical industry (bio Pharma) and its ability to generate returns from investment in innovative new medicines. - Since 2021, much of the world has successfully adjusted to life where COVID-19 is more endemic as vaccines and treatments reduced the risk and
Read More
High Inflation is Driving The Deferment of Necessary Medical Care
Inflation continues to be a burden – food, gas, holiday spending, new year’s goals This past year has been especially challenging as inflation costs continue to touch all aspects of daily life, leading to tough choices for many consumers as we finished the holiday season and look to goals and planning for 2023. In fact, two out of five (40%) survey respondents said inflation changed the way they shopped for the holidays. As consumers adjust their spending habits, many are finding
Read More
Caris Life Sciences and ConcertAI Partner to Accelerate Drug Development and Novel Research
What You Should Know: - Caris Life Sciences®(Caris), a molecular science, artificial intelligence (AI) and machine learning technology company actively developing and delivering innovative solutions to revolutionize healthcare, and ConcertAI, an oncology real-world evidence data and AI technology company, announced a unique partnership to align the two companies' oncology capabilities. - The strategic partnership will create one of the largest translational and clinical
Read More
Biomica Raises $20M to Advance its Pipeline of Microbiome-based Therapeutics
What You Should Know: - Biomica, a clinical-stage biopharmaceutical company developing innovative microbiome-based therapeutics and a subsidiary of Evogene Ltd raises $20M led by Shanghai Healthcare Capital (SHC). - The financing round will enable Biomica to forge ahead, developing its pipeline of microbiome-based therapeutics. Biomica plans to use the proceeds to complete its current BMC128 phase 1 immuno-oncology study and advance to phase 2 clinical trial; scale up and complete GMP
Read More
Merck Invests in Gesund, Launches Medical AI Platform on AWS
What You Should Know: - Gesund, the company ensuring that medical artificial intelligence (AI) is safe and effective for all, today announced the securing of a strategic investment from Merck as well as a launch of a new commercial platform on Amazon Web Services Marketplace. - While terms of the investment are not being disclosed, the news signals support for the company's approach as it launches a first of its kind commercial platform on Amazon Web Services Marketplace, immediately
Read More
BrightInsight Adds Xealth, Woebot Health and Claritas Rx to the BrightInsight Ecosystem
- BrightInsight, Inc., a global platform for biopharma and medtech regulated digital health solutions, recently announced the expansion of its recently launched BrightInsight Ecosystem, a network of the world’s leading healthcare and technology companies collaborating to solve healthcare’s biggest challenges to drive digital innovation, adoption and engagement. - In addition, BrightInsight is proud to be a part of General Catalyst’s Health Assurance network—comprised of healthcare technology
Read More
Elevation Oncology Secures $50M Loan Facility with K2 HealthVentures
What You Should Know: Elevation Oncology, a clinical-stage biopharmaceutical company focused on the development of precision oncology products for patients with genomically defined cancers, today announced that it has secured a $50M senior secured loan facility from funds managed by K2 HealthVentures. Elevation plans to use the funding from the facility will primarily support the exclusive license of EO-3021 (SYSA1801) outside of Greater China from CSPC Pharmaceutical Group and the
Read More
Syapse Raises $35M to Expand Learning Health Network
What You Should Know: - Syapse raises $35M led by an affiliate of Innovatus Capital Partners, LLC (Innovatus)to tackle the challenge of understanding, preventing, and treating complex cancers. - The investment will allow Syapse to expand its artificial intelligence and machine learning capabilities, making it more efficient to uncover meaningful insights from real-world oncology data. Syapse, a San Francisco, CA-based real-world evidence company accelerating the
Read More
Merck Digital Sciences Studio Launches to Support Biomedical Startups
What You Should Know: - Merck, today announced the launch of the Merck Digital Sciences Studio (MDSS) to enable the generation of innovative technologies for drug discovery and development. - MDSS will support early-stage biomedical startups with direct investment, access to powerful Azure Cloud computing and opportunities to pilot their technologies in collaboration with discovery and clinical scientists at Merck. MDSS Accelerator Program Focus The MDSS is a collaboration between
Read More
